作者
Alysia N Lozano-Ondoua, Courtney Wright, Anna Vardanyan, Tamara King, Tally M Largent-Milnes, Mark Nelson, Juan Miguel Jimenez-Andrade, Patrick W Mantyh, Todd W Vanderah
发表日期
2010/4/24
期刊
Life sciences
卷号
86
期号
17-18
页码范围
646-653
出版商
Pergamon
简介
AIMS
Cannabinoid CB2 agonists have been shown to alleviate behavioral signs of inflammatory and neuropathic pain in animal models. AM1241, a CB2 agonist, does not demonstrate central nervous system side effects seen with CB1 agonists such as hypothermia and catalepsy. Metastatic bone cancer causes severe pain in patients and is treated with analgesics such as opiates. Recent reports suggest that sustained opiates can produce paradoxical hyperalgesic actions and enhance bone destruction in a murine model of bone cancer. In contrast, CB2 selective agonists have been shown to reduce bone loss associated with a model of osteoporosis. Here we tested whether a CB2 agonist administered over a 7day period inhibits bone cancer-induced pain as well as attenuates cancer-induced bone degradation.
MAIN METHODS
A murine bone cancer model was used in which osteolytic sarcoma cells were …
引用总数
2010201120122013201420152016201720182019202020212022202320243101413871022787712
学术搜索中的文章